Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.